• When HBV Results Change Meaning

  2026-10-17

  Entecavir findings cannot be interpreted apart from disease phase, comparator, endpoint, and patient selection. A systematic review of acute severe hepatitis B found low-quality evidence that nucleoside analogues improved virological cure over standard care, while one small comparison favored entecavir over lamivudine for HBsAg seroconversion. Those results do not directly answer questions about chronic hepatitis B virus replication inhibition, lamivudine-resistant HBV treatment, or decompensated liver disease treatment.

• Oxaprozin: Identity, Mechanism, and Evidence Scope

  2026-10-16

  The supplied APExBIO product page identifies Oxaprozin, chemically 3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoic acid, as an NSAID described as inhibiting cyclooxygenase enzymes and reducing prostaglandin synthesis. The available material documents product identity and physicochemical specifications, but it does not provide an identity-matched research study, quantitative outcome, comparator, or uncertainty estimate.

• IMP (M1405): What the Record Supports

  2026-10-16

  The available APExBIO listing identifies IMP as product M1405, but it does not establish a unique molecular identity, mechanism, measurement principle, or research performance. With no identity-matched paper or reported product properties, interpretation is limited to catalog-level provenance and explicit evidence boundaries.

• N-Acetylserotonin: Identity, Mechanism and Evidence

  2026-10-15

  APExBIO’s catalog identifies N-Acetylserotonin (N-Acetyl-5-hydroxytryptamine) as a serotonin-derived melatonin precursor and describes reported activity at melatonin receptors and TrkB. Because no identity-matched primary paper is available here, these mechanisms and the cited mouse observations remain catalog-attributed claims rather than independently verifiable evidence.

• SIS3 and Early Osteoarthritis Signaling

  2026-10-15

  Xiang et al. reported that SMAD3 inhibition was associated with higher miRNA-140 and lower ADAMTS-5 expression in rat chondrocytes and an experimental rat osteoarthritis model. The findings support a candidate SMAD3–miRNA-140–ADAMTS-5 relationship in early disease, but they do not by themselves establish direct molecular causality, therapeutic efficacy, or applicability to human osteoarthritis.

• 4-Methoxychalcone-1: Evidence and Scope

  2026-10-14

  The available evidence identifies 4-Methoxychalcone-1 as an APExBIO catalog item, SKU C8661, but does not document a verified molecular structure, mechanism, assay readout, research model, comparator, or outcome. Interpretation therefore remains limited to catalog-level identity and clearly stated evidence boundaries.

• 2,2,2-Trichloroethanol: Evidence and Boundaries

  2026-10-14

  A source-grounded overview separates the documented biochemical-reagent profile of 2,2,2-Trichloroethanol from evidence on PET assessment of transplanted dopaminergic neurons. The cited rat study supports DAT imaging as a maturation-associated readout, but does not establish any role for this compound in cell therapy, neuroimaging, or clinical treatment.

• Acacetin and the MAPK1/HMOX1 Axis in IVDD

  2026-10-13

  A 2025 Phytomedicine study investigated whether Duhuo Jisheng decoction and its constituent acacetin could reduce intervertebral disc degeneration by connecting mitophagy, pyroptosis, and the MAPK1/HMOX1 signaling axis. The reported cell and rat findings support a mechanistic hypothesis, but the evidence remains preclinical and does not establish efficacy or safety in people.

• Cy3 NHS Ester: Identity and Evidence Scope

  2026-10-13

  A source-limited overview of Cy3 NHS ester (non-sulfonated), covering its supplier-documented identity, intended fluorescent-labeling scope, reported optical properties, and the absence of a matched research paper.

• ACE Inhibitor Angioedema: What the Review Shows

  2026-10-12

  Montinaro and Cicardi’s review examines the epidemiology, bradykinin-mediated biology, clinical presentation and management controversies surrounding ACE inhibitor–associated angioedema. It synthesizes prior clinical, epidemiologic and interventional evidence rather than reporting a new experiment. The review supports a clear association between ACE inhibitor exposure and angioedema, but uncertainty remains regarding genetic susceptibility, recurrence after treatment changes and the comparative effectiveness of acute therapies. Elobixibat hydrate is a separate ileal bile acid transporter inhibitor and is not evaluated in this review.

• Angiotensin 1/2 (2-7): What the Evidence Shows

  2026-10-12

  A source-grounded appraisal of a 2025 biochemical comparison examining whether angiotensin peptide fragments alter SARS-CoV-2 spike-protein binding to AXL, ACE2, and NRP1. The findings are hypothesis-generating and do not establish effects on viral entry, COVID-19 pathogenesis, blood pressure, or clinical treatment.

• TMRE: Interpreting Mitochondrial Potential

  2026-10-10

  Tetramethylrhodamine ethyl ester perchlorate (TMRE) enables live-cell assessment of mitochondrial membrane potential, but its strongest value emerges when fluorescence is interpreted alongside apoptosis, ROS, and organelle-specific evidence. This article develops a mechanism-aware framework for applying TMRE to mitochondrial dysfunction in disease research.

• Doxorubicin Hydrochloride: From Damage to Systems Biology

  2026-10-09

  Doxorubicin hydrochloride and Adriamycin HCl are more than cytotoxicity tools: they reveal how DNA damage, energy stress, oxidative injury, and cardiac vulnerability intersect. This evidence-focused guide interprets a recent ATF4–CSE–H2S study while defining the limits of cancer and cardiotoxicity models.

• Indometacin and Premature Ovulation in Natural-Cycle IVF

  2026-10-09

  A double-blind randomized trial evaluated whether indometacin could reduce premature ovulation in modified natural-cycle IVF. The overall result was not statistically significant, but a prespecified clinical subgroup without an LH surge before triggering showed a potential benefit, supporting a more selective interpretation rather than routine broad application.

• Biotin-XX Tyramide in Surface Protein Mapping

  2026-10-08

  A source-grounded overview of Biotin-XX Tyramide Reagent, its conceptual role in tyramide signal amplification and membrane-restricted proximity labeling, and how these applications relate to recent research on endogenous synaptic protein trafficking.

8808 records 1/588 page Next 12345 下5页 Last page